课题基金 / 基金详情

AN ANIMAL MODEL OF NATURALLY OCCURRING TUMOR IMMUNITY

AN ANIMAL MODEL OF NATURALLY OCCURRING TUMOR IMMUNITY
天然肿瘤免疫的动物模型
批准号:
6209844
负责人:
Matthew L Albert
金额:
$3.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
未结题
起止时间:
2000-08-15 至

项目摘要

项目成果

Matthew L Albert的其他基金

相似基金

相关文献

中文摘要
翻译
副肿瘤小脑变性(PCD)提供了人类自然发生的乳腺肿瘤免疫的重要和独特的例子。PCD的特点是高滴度抗体直接针对肿瘤抗原称为cdr2,通常在小脑表达。PCD患者对其肿瘤产生有效的免疫反应,然后以严重的神经功能障碍引起临床注意。有人提出,当cdr2被识别为乳腺或卵巢肿瘤中的外来抗原时,免疫系统启动PCD。我们假设PCD中发生的肿瘤免疫和神经元破坏不是针对cdr2的抗体的结果,而是细胞毒性T细胞(ctl)杀死表达cdr2细胞的结果。这一假设部分基于研究人员未能通过诱导cdr2抗体创建PCD动物模型,部分基于我们发现能够杀死PCD患者肿瘤的cdr2特异性ctl。我们建议通过建立PCD动物模型来验证这一假设,并加深我们对乳腺肿瘤免疫的理解。由于我们在神经正常个体的乳腺肿瘤中也发现了cdr2的表达,我们的研究为人类乳腺癌免疫提供了一种新的重要途径。
英文摘要
Paraneoplastic cerebellar degeneration (PCD) provides an important and unique example of naturally occurring breast tumor immunity in humans. PCD is characterized by a high titer antibody directed against a tumor antigen termed cdr2 that is normally expressed in the cerebellum. PCD patients develop an effective immune response to their tumors, and then come to clinical attention with severe neurologic dysfunction. It is proposed that the immune system initiates PCD when cdr2 is recognized as a foreign antigen in breast or ovarian tumors. We have hypothesized that the tumor immunity and neuronal destruction that occurs in PCD is not a result of antibodies against cdr2, but instead results from cytotoxic T cells (CTLs) that kill cdr2 expressing cells. This hypothesis is based in part on the failure of investigators to create an animal model of PCD by inducing cdr2 antibodies, and in part on our finding of cdr2-specific CTLs capable of killing tumors in PCD patients. We propose to test this hypothesis and deepen our understanding of breast tumor immunity by generating an animal model of PCD. Since we also find cdr2 expression in breast tumors obtained from neurologically normal individuals, our studies provide a new and important approach to breast cancer immunity in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EFFECTIVE TUMOR IMMUNOTHERAPY IN TRANSITIONAL CELL CARCINOMA OF THE BLADDER
  • 批准号:
    7207016
  • 项目类别:
  • 资助金额:
    $0.1万
  • 财政年份:
    2005
  • 负责人:
    Matthew L Albert
  • 依托单位:
Effective Tumor Immunotherapy in Transitional Cell Carc
  • 批准号:
    7041514
  • 项目类别:
  • 资助金额:
    $0.69万
  • 财政年份:
    2003
  • 负责人:
    Matthew L Albert
  • 依托单位:
AN ANIMAL MODEL OF NATURALLY OCCURRING TUMOR IMMUNITY
  • 批准号:
    6522882
  • 项目类别:
  • 资助金额:
    $4.62万
  • 财政年份:
    2002
  • 负责人:
    Matthew L Albert
  • 依托单位:
AN ANIMAL MODEL OF NATURALLY OCCURRING TUMOR IMMUNITY
  • 批准号:
    6402528
  • 项目类别:
  • 资助金额:
    $4.02万
  • 财政年份:
    2001
  • 负责人:
    Matthew L Albert
  • 依托单位:
海外基金